

Condensed Consolidated Statements of Operations*(in thousands, except per share data)*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2021	2020	2021	2020
Expenses:				
Research and development	\$ 4,221	\$ 4,495	\$ 8,631	\$ 7,956
General and administrative	3,371	3,453	8,040	6,695
Loss on impairment of intangible assets	37,770	-	37,770	-
Total operating expenses	<u>45,362</u>	<u>7,948</u>	<u>54,441</u>	<u>14,651</u>
Operating loss	(45,362)	(7,948)	(54,441)	(14,651)
Other income (expense):				
Interest income	39	5	89	94
Interest expense	(46)	(31)	(87)	(75)
Other (expense), net	(352)	(1,584)	(243)	(1,460)
Total other (expense), net	<u>(359)</u>	<u>(1,610)</u>	<u>(241)</u>	<u>(1,441)</u>
Loss before income taxes	(45,721)	(9,558)	(54,682)	(16,092)
Deferred income tax benefit	8,332	-	8,332	-
Net loss	<u>\$ (37,389)</u>	<u>\$ (9,558)</u>	<u>\$ (46,350)</u>	<u>\$ (16,092)</u>
Net loss per common share				
Basic and diluted	\$ (1.42)	\$ (0.63)	\$ (2.10)	\$ (1.12)
Weighted average number of common shares outstanding				
Basic and diluted	26,350	15,091	22,047	14,394